Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anti-inflammatory
Biotech
AbbVie pays $48M for OSE's preclinical chronic inflammation drug
AbbVie handed OSE the upfront fee and dangled another $665 million in milestones for global rights to a novel approach to chronic inflammation.
Nick Paul Taylor
Feb 28, 2024 5:25am
Union says phase 2 results show psoriasis hopeful has wider use
Jun 21, 2023 10:42am
AbbVie links up with VC firm to map anti-inflammatory companies
Nov 28, 2022 7:30am
Acelyrin brings total raised in 1 year past past $500M mark
Sep 13, 2022 10:05am
Inflammation space swells as Nuvig exits stealth mode with $47M
May 11, 2022 9:05am
Chasing Novartis and Roche, Ventus banks $140M for clinical work
Feb 9, 2022 8:12am